Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers
The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.
You may also be interested in...
Pfizer's decision to bypass UK wholesalers and go direct to pharmacies should ultimately give it better control over product discounting. Other manufacturers are watching closely, and not just in the UK.
Pharma companies say Medicare Part D is a simple trade: increased volume in exchange for decreased prices. Six months into the program, the deal is working out very well for manufacturers-but don't expect anyone to celebrate just yet.
Some industry executives are wondering whether customers on the outpatient side-most notably, pharmacy benefit management companies-are preparing their own consolidation.